| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PTTG2 |
| Uniprot No | Q9NZH5 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-202 aa |
| 活性数据 | ATLIYVDKE IGEPGTRVAA KDVLKLESRP SIKALDGISQ VLTRRFGKTY DAPSALPKAT RKALGTVNRA TEKSVKTNGP RKQKQPSFSA KKMTEKTVKT KSSVPASDDA YPEIEKFFPF NLLDFESFDL PEERQIAHLP LSGVPLMILD EEGELEKLFQ LGPPSPVKMP SPPWECNLLQ SPSSILSTLD VELPAVCYDI DI |
| 分子量 | 22.3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下为3-4篇关于重组人**PTTG2蛋白**的简化参考文献(供参考，具体文献需根据实际发表内容调整)：
---
1. **文献名称**：*"Pituitary Tumor-Transforming Gene 2 (PTTG2) as a Novel Securin: Structural Insights and Functional Implications in Cancer"*
**作者**：Smith, J. et al. (2020)
**摘要**：该综述分析了PTTG2蛋白的分子结构，强调其作为Securin家族成员在有丝分裂中的调控作用，提出其异常表达与多种肿瘤的增殖、转移相关，并探讨其在癌症治疗中的潜在靶点价值。
2. **文献名称**：*"PTTG2 Promotes Ovarian Cancer Cell Invasion by Regulating Epithelial-Mesenchymal Transition"*
**作者**：Zhang, L. et al. (2022)
**摘要**：研究发现，重组人PTTG2蛋白通过激活EMT通路(如上调Snail和Vimentin)增强卵巢癌细胞侵袭能力，抑制PTTG2可显著降低肿瘤转移风险。
3. **文献名称**：*"PTTG2 Interacts with β-Catenin to Drive Wnt Signaling in Colorectal Cancer"*
**作者**：Chen, H. et al. (2018)
**摘要**：实验证实PTTG2与β-catenin直接结合，激活Wnt/β-catenin信号通路，促进结直肠癌细胞增殖和化疗耐药，为靶向干预提供了理论依据。
4. **文献名称**：*"Tissue-Specific Expression and Hormonal Regulation of Human PTTG2 in Normal and Tumor Tissues"*
**作者**：Vázquez-Borrego, M.C. et al. (2001)
**摘要**：较早研究报道PTTG2的组织特异性表达模式，发现在睾丸和某些癌组织中高表达，并受激素(如雄激素)调控，提示其在生殖系统肿瘤中的作用。
---
**注**：以上为模拟参考文献框架，实际文献需通过PubMed/Google Scholar搜索核实，关键词建议：**"PTTG2"、"recombinant PTTG2"、"Securin"、"cancer"**。
**Recombinant Human PTTG2 Protein: Background Overview**
Pituitary Tumor-Transforming Gene 2 (PTTG2), also known as securin, belongs to the securin family of proteins that play pivotal roles in regulating cell cycle progression and genomic stability. Primarily expressed during the G2/M phase, PTTG2 is involved in sister chromatid separation by binding to separase, a protease critical for cohesin cleavage. Its transient overexpression ensures accurate chromosome segregation, while dysregulation is linked to mitotic errors, aneuploidy, and oncogenesis. Unlike its paralog PTTG1 (a well-studied oncogene), PTTG2 exhibits tissue-specific expression and distinct regulatory mechanisms, though both share roles in promoting tumorigenesis and metastasis.
Recombinant human PTTG2 protein is engineered using prokaryotic or eukaryotic expression systems (e.g., *E. coli* or mammalian cells) to ensure proper folding and post-translational modifications. This protein retains functional domains necessary for separase interaction, making it valuable for *in vitro* studies. Researchers employ it to dissect molecular mechanisms of chromosome segregation, cell cycle checkpoints, and apoptosis. Additionally, PTTG2’s involvement in cancer pathways, stem cell pluripotency, and DNA repair highlights its potential as a therapeutic target or biomarker. Its recombinant form enables drug screening, antibody development, and structural studies to elucidate interactions within mitotic regulatory networks.
Ongoing research focuses on PTTG2’s dual roles in tumor suppression and progression, emphasizing context-dependent behavior influenced by cellular stress and signaling crosstalk.
×
